WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

The employees at WuXi Biologics have once again shown their commitment to the local community with their fourth annual ...

A proposed sale to a larger credit union is being put before the Dundalk District Credit Union membership for a decision in two weeks’ time. The annual general and special meeting is to take ...

“We are excited to join the WuXi Global Forum to share our unique approach to drug discovery and discuss the progress of our differentiated pipeline for both its internal drug pipeline and its ...

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth and improved margins. Although the newsthat WuXi Bio ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies ...